Zacks Investment Research Upgrades Kadmon Holdings Inc (KDMN) to “Buy”

Kadmon Holdings Inc (NASDAQ:KDMN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage currently has a $3.00 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 2.04% from the stock’s previous close.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

Other equities analysts have also recently issued reports about the stock. Citigroup Inc. lowered their price target on shares of Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating on the stock in a report on Monday, March 27th. WBB Securities upgraded shares of Kadmon Holdings from a “sell” rating to a “hold” rating and set a $3.25 price target on the stock in a report on Thursday, March 16th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $23.00 price target (down from $36.10) on shares of Kadmon Holdings in a report on Thursday, March 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Kadmon Holdings presently has a consensus rating of “Buy” and an average target price of $12.04.

Analyst Recommendations for Kadmon Holdings (NASDAQ:KDMN)

Kadmon Holdings (KDMN) opened at 2.94 on Tuesday. Kadmon Holdings has a 12 month low of $2.25 and a 12 month high of $11.73. The stock’s market capitalization is $152.43 million. The company has a 50 day moving average price of $2.61 and a 200 day moving average price of $3.64.

Kadmon Holdings (NASDAQ:KDMN) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $4.25 million. The business’s quarterly revenue was down 42.3% on a year-over-year basis. Equities research analysts predict that Kadmon Holdings will post ($1.75) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Kadmon Holdings Inc (KDMN) to “Buy”” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/2654066/zacks-investment-research-upgrades-kadmon-holdings-inc-kdmn-to-buy.html.

Large investors have recently modified their holdings of the company. Perceptive Advisors LLC boosted its stake in shares of Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock worth $18,772,000 after buying an additional 2,976,190 shares in the last quarter. KCG Holdings Inc. acquired a new stake in shares of Kadmon Holdings during the first quarter worth about $124,000. Renaissance Technologies LLC acquired a new stake in shares of Kadmon Holdings during the first quarter worth about $158,000. Vanguard Group Inc. boosted its stake in shares of Kadmon Holdings by 2,046.1% in the first quarter. Vanguard Group Inc. now owns 567,320 shares of the company’s stock worth $2,053,000 after buying an additional 540,885 shares in the last quarter. Finally, AE Wealth Management LLC acquired a new stake in shares of Kadmon Holdings during the first quarter worth about $391,000.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:KDMN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Kadmon Holdings (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.